

Guido Martignoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6109775/publications.pdf>

Version: 2024-02-01

121
papers

7,646
citations

46984

47
h-index

53190

85
g-index

124
all docs

124
docs citations

124
times ranked

6104
citing authors

#	ARTICLE	IF	CITATIONS
1	PEComas: the past, the present and the future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 119-132.	1.4	448
2	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. <i>European Urology</i> , 2015, 67, 85-97.	0.9	403
3	A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1395-1406.	2.1	379
4	Clear Cell "Sugar" Tumor of the Pancreas. <i>American Journal of Surgical Pathology</i> , 1996, 20, 722-730.	2.1	351
5	Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1239-1245.	2.1	252
6	Apparent Renal Cell Carcinomas in Tuberous Sclerosis Are Heterogeneous. <i>American Journal of Surgical Pathology</i> , 1998, 22, 180-187.	2.1	250
7	Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. <i>Pathology</i> , 1991, 23, 185-188.	0.3	220
8	Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 161-176.	2.1	219
9	Abdominopelvic Sarcoma of Perivascular Epithelioid Cells. Report of Four Cases in Young Women, One with Tuberous Sclerosis. <i>Modern Pathology</i> , 2001, 14, 563-568.	2.9	191
10	Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. <i>Modern Pathology</i> , 2005, 18, 161-169.	2.9	186
11	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. <i>Journal of Experimental Medicine</i> , 2014, 211, 2249-2263.	4.2	170
12	The Perivascular Epithelioid Cell and Related Lesions. <i>Advances in Anatomic Pathology</i> , 1997, 4, 343-358.	2.4	143
13	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. <i>Modern Pathology</i> , 2014, 27, 875-886.	2.9	136
14	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1113-1120.	0.5	135
15	Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. <i>Modern Pathology</i> , 2006, 19, 488-493.	2.9	126
16	Perivascular Epithelioid Cell Tumors (PEComas) Harboring TFE3 Gene Rearrangements Lack the TSC2 Alterations Characteristic of Conventional PEComas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 783-784.	2.1	125
17	Gains of Chromosomes 7, 17, 12, 16, and 20 and Loss of Y Occur Early in the Evolution of Papillary Renal Cell Neoplasia: A Fluorescent In Situ Hybridization Study. <i>Modern Pathology</i> , 2003, 16, 1053-1059.	2.9	121
18	Perivascular Epithelioid Cell. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1149-1153.	2.1	121

#	ARTICLE	IF	CITATIONS
19	Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 133-139.	0.6	112
20	Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. <i>Modern Pathology</i> , 2011, 24, 1313-1319.	2.9	112
21	Renal Disease in Adults With TSC2/PKD1 Contiguous Gene Syndrome. <i>American Journal of Surgical Pathology</i> , 2002, 26, 198-205.	2.1	105
22	Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. <i>Modern Pathology</i> , 2012, 25, 100-111.	2.9	105
23	Parvalbumin Is Constantly Expressed in Chromophobe Renal Carcinoma. <i>Modern Pathology</i> , 2001, 14, 760-767.	2.9	104
24	Metanephric Adenoma Lacks the Gains of Chromosomes 7 and 17 and Loss of Y That Are Typical of Papillary Renal Cell Carcinoma and Papillary Adenoma. <i>Modern Pathology</i> , 2003, 16, 1060-1063.	2.9	101
25	Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2008, 21, 1-6.	2.9	97
26	Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. <i>Modern Pathology</i> , 2006, 19, 780-787.	2.9	92
27	Prognostic Value of Renal Cell Carcinoma Nuclear Grading: Multivariate Analysis of 333 Cases. <i>Urologia Internationalis</i> , 2001, 67, 130-134.	0.6	90
28	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 7226-7233.	3.2	89
29	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	1.1	89
30	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	0.8	89
31	Cathepsin-k expression in pulmonary lymphangiomyomatosis. <i>Modern Pathology</i> , 2009, 22, 161-166.	2.9	88
32	Renal Cell Carcinoma With Clear Cell and Papillary Features. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 391-399.	1.2	83
33	A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. <i>Histopathology</i> , 2017, 71, 42-52.	1.6	79
34	Mit Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. <i>Cancers</i> , 2019, 11, 1110.	1.7	79
35	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1384-1389.	2.1	77
36	Cellular heterogeneity in lymphangiomyomatosis of the lung. <i>Human Pathology</i> , 1991, 22, 727-728.	1.1	76

#	ARTICLE	IF	CITATIONS
37	Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. <i>Modern Pathology</i> , 2007, 20, 303-309.	2.9	76
38	Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. <i>Modern Pathology</i> , 2007, 20, 722-728.	2.9	72
39	Clear Cell Papillary Renal Cell Carcinoma-like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1131-1139.	2.1	70
40	CD10 is expressed in a subset of chromophobe renal cell carcinomas. <i>Modern Pathology</i> , 2004, 17, 1455-1463.	2.9	67
41	Oncocytoma-like Angiomyolipoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 610-612.	1.2	62
42	Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. <i>Human Pathology</i> , 2014, 45, 1130-1138.	1.1	61
43	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
44	Implant based differences in adverse local tissue reaction in failed total hip arthroplasties: a morphological and immunohistochemical study. <i>BMC Clinical Pathology</i> , 2014, 14, 39.	1.8	56
45	PEComas of the kidney and of the genitourinary tract. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 140-159.	1.0	56
46	Molecular Pathology of Lymphangiomyomatosis and Other Perivascular Epithelioid Cell Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 33-40.	1.2	54
47	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49
48	t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. <i>Modern Pathology</i> , 2018, 31, 474-487.	2.9	49
49	Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. <i>Cancer Cytopathology</i> , 2019, 127, 52-61.	1.4	49
50	Gleason and Fuhrman no longer make the grade. <i>Histopathology</i> , 2016, 68, 475-481.	1.6	48
51	Renal pathology in the tuberous sclerosis complex. <i>Pathology</i> , 2003, 35, 505-512.	0.3	45
52	A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. <i>American Journal of Clinical Pathology</i> , 2013, 139, 151-159.	0.4	44
53	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 409-418.	1.4	42
54	Diagnostic Usefulness of Fluorescent Cytogenetics in Differentiating Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. <i>American Journal of Clinical Pathology</i> , 2010, 133, 116-126.	0.4	41

#	ARTICLE	IF	CITATIONS
55	Digital reporting of whole-slide images is safe and suitable for assessing organ quality in preimplantation renal biopsies. <i>Human Pathology</i> , 2016, 47, 115-120.	1.1	41
56	The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. <i>Modern Pathology</i> , 2021, 34, 1444-1455.	2.9	41
57	Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 419-426.	1.5	40
58	A distinctive translocation carcinoma of the kidney; â€œrosette forming,â€•t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. <i>Human Pathology</i> , 2012, 43, 726-736.	1.1	37
59	iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona. <i>Diagnostic Pathology</i> , 2014, 9, S12.	0.9	36
60	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020, 52, 297-309.	0.3	35
61	Vimentin Reactivity in Renal Oncocytoma: Immunohistochemical Study of 234 Cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 1782-1788.	1.2	35
62	Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. <i>Modern Pathology</i> , 2014, 27, 765-774.	2.9	32
63	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. <i>Pathology</i> , 2017, 49, 10-18.	0.3	30
64	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , 2017, 83, 237-246.	1.3	30
65	Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. <i>Molecular and Clinical Oncology</i> , 2014, 2, 575-580.	0.4	27
66	VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations. <i>Modern Pathology</i> , 2019, 32, 258-268.	2.9	27
67	Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature. <i>Journal of Pediatric Surgery</i> , 2012, 47, e31-e40.	0.8	26
68	TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. <i>Modern Pathology</i> , 2021, 34, 842-850.	2.9	26
69	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	0.8	26
70	Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. <i>Modern Pathology</i> , 2008, 21, 498-504.	2.9	25
71	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II ± , survivin, and E-cadherin. <i>Human Pathology</i> , 2016, 57, 78-84.	1.1	24
72	Angiomyolipoma of the kidney: from simple hamartoma to complex tumour. <i>Pathology</i> , 2021, 53, 129-140.	0.3	23

#	ARTICLE	IF	CITATIONS
73	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	2.1	22
74	The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLoS ONE, 2015, 10, e0114856.	1.1	22
75	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget, 2017, 8, 54096-54105.	0.8	22
76	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. PLoS ONE, 2015, 10, e0127908.	1.1	21
77	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells <i>in vitro</i> and correlating with progression <i>in vivo</i> . Oncotarget, 2016, 7, 74189-74202.	0.8	21
78	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	0.9	20
79	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
80	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973.	2.2	20
81	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Modern Pathology, 2022, 35, 376-385.	2.9	19
82	Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors. Cancers, 2021, 13, 2441.	1.7	19
83	Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. Histology and Histopathology, 2011, 26, 1207-13.	0.5	16
84	Primary seminal vesicle carcinoma. The usefulness of PAX8 immunohistochemical expression for the differential diagnosis. Human Pathology, 2017, 69, 123-128.	1.1	14
85	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 74, 377-390.	1.6	14
86	Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. Modern Pathology, 2021, 34, 2055-2063.	2.9	14
87	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 687-693.	1.4	13
88	Tamoxifen related Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A case report and literature review of this possible association. Pathology Research and Practice, 2019, 215, 1089-1092.	1.0	13
89	Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 55-59.	1.4	12
90	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutic Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	0.7	10

#	ARTICLE	IF	CITATIONS
91	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	0.6	10
92	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 269-273.	1.2	10
93	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 569-577.	1.6	9
94	Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. , 2007, 29, 41-9.		8
95	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: â€œGame Overâ€™?. <i>Targeted Oncology</i> , 2016, 11, 431-446.	1.7	7
96	Stimulator of interferon genes (STING) immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. <i>Pathology</i> , 2021, 53, 579-585.	0.3	7
97	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	0.7	7
98	Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia. <i>Biomedicines</i> , 2022, 10, 1332.	1.4	7
99	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. <i>Apmis</i> , 2016, 124, 619-623.	0.9	6
100	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
101	Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 316-323.	0.6	6
102	Donor kidneys with miliary papillary renal cell neoplasia: The role of the pathologist in determining suitability for transplantation. <i>Annals of Transplantation</i> , 2014, 19, 362-366.	0.5	6
103	Adenocarcinoma of the paraurethral glands: a case report. <i>Histology and Histopathology</i> , 2014, 29, 1295-303.	0.5	6
104	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. <i>Diagnostics</i> , 2020, 10, 123.	1.3	5
105	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , 2019, 72, 573-578.	1.0	4
106	Parvalbumin immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 785-791.	1.4	4
107	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. <i>American Journal of Cancer Research</i> , 2014, 4, 907-15.	1.4	4
108	Discovering smoking-related pathway alterations in urothelial cell carcinoma pathogenesis. <i>Cell Cycle</i> , 2013, 12, 1483-1483.	1.3	3

#	ARTICLE	IF	CITATIONS
109	Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology. <i>BJU International</i> , 2018, 122, 914-915.	1.3	2
110	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. <i>Eur Urol</i> 2021;79:225-31. <i>European Urology</i> , 2021, 80, e17-e18.	0.9	2
111	Identification of a novel mutation (c279delC) and a polymorphism (c291C>G) in the von Hippel-Lindau gene in Italian patients. <i>Human Mutation</i> , 2000, 15, 582-582.	1.1	1
112	Molecular diagnosis of renal cell neoplasms: the usefulness of immunohistochemistry and fluorescence in situ hybridization. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 665-676.	1.6	1
113	Rare MDM2 amplification in a fat-predominant angiomyolipoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 661-666.	1.4	1
114	Epithelioid angiomyolipoma: a pathological entity discovered in Verona with the endorsement of Doctor Rosai. <i>Pathologica</i> , 2021, 113, 307-315.	1.3	1
115	Reply: Gleason and Fuhrman no longer make the grade. <i>Histopathology</i> , 2016, 69, 341-342.	1.6	0
116	â™™Mesenchymal Tumors of the Kidney. , 2019, , 203-212.		0
117	Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 480-480.	0.8	0
118	Clear Cell Papillary Renal Cell Carcinoma. <i>Encyclopedia of Pathology</i> , 2019, , 1-2.	0.0	0
119	Angiomyolipoma. <i>Encyclopedia of Pathology</i> , 2020, , 7-9.	0.0	0
120	Clear Cell Papillary Renal Cell Carcinoma. <i>Encyclopedia of Pathology</i> , 2020, , 29-30.	0.0	0
121	Carcinoma of Unknown Primary Site With Papillary Renal Cell Carcinoma Features and Without a Kidney Primary Lesion: A Diagnostic and Therapeutic Challenge. <i>Urology</i> , 2022, , .	0.5	0